Bioinformatics Analysis of the Molecular Mechanism and Potential Treatment Target of Ankylosing Spondylitis

被引:6
|
作者
Meng, Fanyan [1 ]
Du, Ningna [1 ]
Xu, Daoming [1 ]
Kuai, Li [1 ]
Liu, Lanying [1 ]
Xiu, Minning [2 ]
机构
[1] Jiangsu Prov Hosp Tradit Chinese Med, Dept Acupuncture & Rehabil, Nanjing, Peoples R China
[2] Jiangsu Prov Hosp Tradit Chinese Med, Dept Nursing, 155 Hanzhong Rd, Nanjing, Peoples R China
关键词
GENES; CD4; RNA;
D O I
10.1155/2021/7471291
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Ankylosing spondylitis (AS) is an autoimmune disease that mainly affects the spinal joints, sacroiliac joints, and adjacent soft tissues. We conducted bioinformatics analysis to explore the molecular mechanism related to AS pathogenesis and uncover novel potential molecular targets for the treatment of AS. The profiles of GSE25101, containing gene expression data extracted from the blood of 16 AS patients and 16 matched controls, were acquired from the Gene Expression Omnibus (GEO) database. The background correction and standardization were carried out utilizing the transcript per million (TPM) method. After analysis of AS patients and the normal groups, we identified 199 differentially expressed genes (DEGs) with upregulation and 121 DEGs with downregulation by the limma R package. The results of the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and Gene Ontology (GO) biological process enrichment analysis revealed that the DEGs with upregulation were mainly associated with spliceosome, ribosome, RNA-catabolic process, electron transport chain, etc. And the DEGs with downregulation primarily participated in T cell-associated pathways and processes. After analysis of the protein-protein interaction (PPI) network, our data revealed that the hub genes, comprising MRPL13, MRPL22, LSM3, COX7A2, COX7C, EP300, PTPRC, and CD4, could be the treatment targets in AS. Our data furnish new hints to uncover the features of AS and explore more promising treatment targets towards AS.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] TREATMENT OF ANKYLOSING-SPONDYLITIS
    ROSS, WM
    BRITISH JOURNAL OF RADIOLOGY, 1979, 52 (616): : 330 - 330
  • [42] Etoricoxib in the treatment of ankylosing spondylitis (AS).
    Melian, A
    van der Heijde, DM
    James, MK
    Calin, A
    Giallella, KM
    Reicin, AS
    Dougados, M
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S432 - S432
  • [43] Modern treatment of ankylosing spondylitis
    Rehart, S.
    Kerschbaumer, F.
    Braun, J.
    Sieper, J.
    ORTHOPADE, 2007, 36 (10): : 963 - 972
  • [44] Treatment guidelines for ankylosing spondylitis
    Christopher T. Ritchlin
    Current Rheumatology Reports, 2004, 6 (2) : 96 - 97
  • [45] TREATMENT OF ANKYLOSING-SPONDYLITIS
    SADOWSKAWROBLEWSKA, M
    ZEITSCHRIFT FUR KLINISCHE MEDIZIN-ZKM, 1988, 43 (01): : 7 - 10
  • [46] Treatment of ankylosing spondylitis with infliximab
    Boeger, CA
    Wittwer, H
    Schattenkirchner, M
    Kellner, H
    Kellner, W
    ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (12) : 1159 - 1160
  • [47] TREATMENT OF ANKYLOSING-SPONDYLITIS
    GOLDING, JR
    PRACTITIONER, 1972, 208 (1243) : 57 - &
  • [48] ORTHOPAEDIC TREATMENT OF ANKYLOSING SPONDYLITIS
    KUIPERS, RKW
    LANCET, 1945, 249 (DEC15): : 774 - 775
  • [49] Treatment of ankylosing spondylitis with moxifloxacin
    Ogrendik, Mesut
    SOUTHERN MEDICAL JOURNAL, 2007, 100 (04) : 366 - 370
  • [50] A new mechanism or injury in ankylosing spondylitis
    Samartzis, D.
    Modi, H. N.
    Cheung, K. M. C.
    Luk, K. D. K.
    BONE & JOINT JOURNAL, 2013, 95B (02): : 206 - 209